Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics Inc (DRMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,431
  • Shares Outstanding, K 2,835
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,560 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-1.92
  • Growth Rate Est. (year over year) +52,131.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +9.09%
on 03/30/26
1.8400 -34.78%
on 03/20/26
unch (unch)
since 02/27/26
3-Month
1.1000 +9.09%
on 03/30/26
4.6600 -74.25%
on 01/26/26
-1.1200 (-48.28%)
since 12/31/25
52-Week
1.1000 +9.09%
on 03/30/26
10.8440 -88.93%
on 04/02/25
-8.7970 (-88.00%)
since 04/01/25

Most Recent Stories

More News
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical...

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata to Present on BioPub on January 31, 2025

- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
RVNC : 3.65 (+0.27%)
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne -

DRMAW : 0.0157 (-7.65%)
DRMA : 1.2000 (-0.83%)

Business Summary

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

See More

Key Turning Points

3rd Resistance Point 1.3603
2nd Resistance Point 1.3083
1st Resistance Point 1.2541
Last Price 1.2000
1st Support Level 1.1479
2nd Support Level 1.0959
3rd Support Level 1.0417

See More

52-Week High 10.8440
Fibonacci 61.8% 7.1218
Fibonacci 50% 5.9720
Fibonacci 38.2% 4.8222
Last Price 1.2000
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.